Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RTSL's EV-to-EBIT is not ranked *
in the Diversified Financial Services industry.
Industry Median: 4.075 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Rapid Therapeutic Science Laboratories's Enterprise Value for the quarter that ended in Jun. 2023 was $4.35 Mil.
Rapid Therapeutic Science Laboratories's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Therapeutic Science Laboratories EV-to-EBIT Related Terms
Rapid Therapeutic Science Laboratories EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Shell Companies subindustry, Rapid Therapeutic Science Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Therapeutic Science Laboratories EV-to-EBIT vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Rapid Therapeutic Science Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Rapid Therapeutic Science Laboratories's EV-to-EBIT falls into.
Rapid Therapeutic Science Laboratories's current Enterprise Value is $0.00 Mil.
Rapid Therapeutic Science Laboratories's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Therapeutic Science Laboratories (RTSL) has a EV-to-EBIT of 0.00 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rapid Therapeutic Science Laboratories and its competitors.
Is Rapid Therapeutic Science Laboratories' EV-to-EBIT too high?
Rapid Therapeutic Science Laboratories' current EV-to-EBIT is 0.00.
How does Rapid Therapeutic Science Laboratories' EV-to-EBIT compare to VRAYQ and NNMX?
Rapid Therapeutic Science Laboratories' EV-to-EBIT of 0.00 can be compared against companies in the Diversified Financial Services industry. The industry median EV-to-EBIT is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Diversified Financial Services company?
The median EV-to-EBIT among Diversified Financial Services companies is 4.08, based on 144 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rapid Therapeutic Science Laboratories and its competitors. For the Diversified Financial Services industry, the median EV-to-EBIT is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Therapeutic Science Laboratories's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Therapeutic Science Laboratories stock overvalued right now?
Rapid Therapeutic Science Laboratories (RTSL) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Rapid Therapeutic Science Laboratories (RTSL), the current EV-to-EBIT is 0.00 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RTSL has been successfully added to your 
